Patents by Inventor Carlin Long

Carlin Long has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CARBON-NANOTUBE MODULATION OF MYOCYTE CELLS
    Publication number: 20170145384
    Abstract: Embodiments include compositions of carbon nanotubes complexed with myocyte cells. Embodiments also include methods for making compositions of carbon nanotubes, and methods for modulating the electrophysical, proliferative, and viability potential of myocytes.
    Type: Application
    Filed: December 15, 2016
    Publication date: May 25, 2017
    Inventors: Luisa Mestroni, Laura Ballerini, Carlin Long, John Caldwell, Maurizio Prato, Valentina Martinelli, Giada Cellot, Francesca Maria Toma, Lorena Zentilin
  • CARBON-NANOTUBE MODULATION OF MYOCYTE CELLS
    Publication number: 20140087461
    Abstract: Embodiments include compositions of carbon nanotubes complexed with myocyte cells. Embodiments also include methods for making compositions of carbon nanotubes, and methods for modulating the electrophysical, proliferative, and viability potential of myocytes.
    Type: Application
    Filed: March 13, 2012
    Publication date: March 27, 2014
    Applicants: UNIVERSITY OF TRIESTE, INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, THE REGENTS OFTHE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Luisa Mestroni, Laura Ballerini, Carlin Long, John Caldwell, Maurizio Prato, Valentina Martinelli, Giada Cellot, Francesca Maria Toma, Lorena Zentilin
  • Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
    Publication number: 20060069014
    Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
    Type: Application
    Filed: August 30, 2005
    Publication date: March 30, 2006
    Inventors: Carlin Long, Eric Olson, Michael Bristow, Timothy McKinsey
  • Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
    Publication number: 20060025333
    Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
    Type: Application
    Filed: July 26, 2005
    Publication date: February 2, 2006
    Inventors: Carlin Long, Eric Olson, Michael Bristow, Timothy McKinsey
  • Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
    Patent number: 6946441
    Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: September 20, 2005
    Assignees: Regents of the University of Colorado, A Body Corporation, The Board of Regents, The University of Texas System
    Inventors: Carlin Long, Eric N. Olson, Michael Bristow, Timothy A. McKinsey
  • Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
    Publication number: 20040186049
    Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
    Type: Application
    Filed: March 16, 2004
    Publication date: September 23, 2004
    Applicants: Regents of the University of Colorado, A body Corporate,, The Board of Regents, The University of Texas System
    Inventors: Carlin Long, Eric N. Olson, Michael Bristow, Timothy A. McKinsey
  • Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
    Patent number: 6706686
    Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
    Type: Grant
    Filed: September 26, 2002
    Date of Patent: March 16, 2004
    Assignee: The Regents of the University of Colorado
    Inventors: Carlin Long, Eric N. Olson, Michael Bristow, Timothy A. McKinsey
  • Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
    Publication number: 20030144340
    Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
    Type: Application
    Filed: September 26, 2002
    Publication date: July 31, 2003
    Applicants: The Regents of the University of Colorado, a Body Corporate, Board of Regents, The University of Texas System
    Inventors: Carlin Long, Eric N. Olson, Michael Bristow, Timothy A. McKinsey